Song Ruilin, Executive President of China Pharmaceutical Innovation Promotion Association: Thinking and Optimizing my country's Innovative Drug Policy Environment from the Perspective of the Whole Chain

People's Political Consultative Conference Network, Beijing, February 12 (Reporter Fu Zhenqiang) "Supporting domestic pharmaceutical innovation can not only stop at me too, but also encourage domestic pharmaceutical companies to achieve me better me best
.

" · At the symposium on "Improving the Ecology of Pharmaceutical Innovation and Promoting the Healthy Development of the Industry" hosted by the People's Political Consultative Conference.

People's Political Consultative Conference Network Beijing, February 12th

Song Ruilin, a specially-appointed expert from the National Committee of the Chinese People's Political Consultative Conference and the executive chairman of the China Pharmaceutical Innovation Promotion Association, delivered a speech at the symposium
.

Photo by Qi Bo, a reporter from the People's Political Consultative Conference and the People's Political Consultative Conference Network

Song Ruilin, a specially-appointed expert from the National Committee of the Chinese People's Political Consultative Conference and the executive chairman of the China Pharmaceutical Innovation Promotion Association, delivered a speech at the symposium

However, Song Ruilin said that the spring of domestic innovative drugs has indeed come, but not every day is sunny, and cloudy weather often occurs.
China's pharmaceutical innovation still faces many challenges
.

He believes that the first challenge is the biggest change compared to 5 years ago.

"China's pharmaceutical innovation still has a lot of room to be released under the existing system
.

" In Song Ruilin's view, another challenge is the domestic medicine itself.

"China has a large population, a large market, and the people's ability to pay is limited.
According to the current medical insurance policy, drugs covered by medical insurance should have lower prices
.

However, only 30% of drugs covered by medical insurance can smoothly enter the hospital, which means that many Medicines may be blocked in the 'last mile'

How to further optimize the ecological environment of domestic pharmaceutical innovation? Song Ruilin believes that there must be a whole chain of thinking
.

Drug regulatory reform should be guided by clinical needs, effectively guide pharmaceutical innovation, and truly match the needs

"The number of domestic innovative drugs approved in one year has reached about 20.
Can they be used in medical institutions for clinical use once they are approved?" In Song Ruilin's view, the "one product, two regulations" system of medical institutions has good intentions, but some Under the circumstance, the scope of hospital procurement of medicines is limited, and innovation is objectively inhibited
.

"Of course, the payment ratio should also be changed for
innovative drugs.

Can a class of innovative drugs be reimbursed 60% or 50%, so that some people can get some funding

Song Ruilin also suggested that to vigorously develop commercial insurance, the China Banking and Insurance Regulatory Commission should clearly include innovative drugs in commercial medical insurance and health insurance
.

Whether innovative drugs can not occupy the proportion of "one product and two regulations", the hospital can let it go and let patients have a choice

"For domestic innovative drugs to go out, the government needs to promote and lead, and enterprises need to follow up
.
Our vaccines have been internationally certified, and I believe that our innovative drugs can also benefit the world
.
" In Song Ruilin's view, it is very important to continuously optimize the internal environment.
, China needs to enter the 2.
0 stage in terms of innovative drug policy
.